Skip to main content

BioMedNewsBreaks – Ocean Biomedical Inc. (NASDAQ: OCEA) Shares Promising Results on World Lung Cancer Day

On World Lung Cancer Day, Ocean Biomedical (NASDAQ: OCEA) shared details of its multipronged lung cancer program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. According to the announcement, Dr. Elias and his team have revealed that Chitinase 3-like-1 (“CHi3L1”) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. The programs suppress primary and metastatic tumor growth in numerous animal models and hold potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in lung cancer mouse models. “We are making discoveries that we believe will drive cancer research, and eventually treatment and patient outcomes, forward,” said Dr. Elias. “This pathway discovery is an unprecedented leap, because if you control CHi3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.”

To view the full press release, visit

About Ocean Biomedical Inc.

Ocean Biomedical is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. For more information about the company, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.